Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

What happens to AF patients who skip the big study?

NCT ID NCT06249269

Knowledge-focused Sponsor: Ratika Parkash Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 198 people with symptomatic atrial fibrillation (AF) who decided not to join a larger trial comparing aggressive risk management plus ablation versus ablation alone. Researchers will track their hospital visits, emergency department stays, and AF episodes over time. The goal is to see if these patients have different health outcomes and quality of life compared to those who joined the main trial.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 198 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2024

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with persistent or paroxysmal AF requiring catheter ablation and meet the inclusion/exclusion criteria for RASTA-AF, but decline or are not approached for participation in the Randomized Clinical Trial will be asked to participate in RASTA Cohort.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * symptomatic AF (CCS-SAF ≥2), * paroxysmal or persistent atrial fibrillation despite rate control, desiring catheter ablation and either: i) BMI ≥ 30 or, ii) at least two of the following: BMI\>27, BP\>140/90 mmHg or history of hypertension, Diabetes, Heart failure (prior heart failure admission or LVEF\<40%), Age ≥ 65 years, Prior stroke/TIA, Current smoker, Excessive alcohol use {For women: 10 or more drinks/week, more than 2 drinks a day (most days). For men: 15 or more drinks/week, more than 3 drinks a day (most days)}, and iii) declined or were not approached for participation in the main study. Eligible patients must have received catheter ablation for AF during the same timeline of the RASTA-AF Mian Study (November 1st, 2019 to December 31st, 2025). Exclusion Criteria: * permanent AF (AF lasting \> 3 years), * prior catheter ablation for AF * New York Heart Association Class IV heart failure * participation in a cardiac rehabilitation program within the last year, * currently performing exercise training \>150 minutes/week of moderate to vigorous physical activity, * unable to exercise, * unable to give informed consent, * other noncardiovascular medical condition making 1 year survival unlikely * less than 18 years of age

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation, paroxysmal or persistent are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial fibrillation, paroxysmal or persistent

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    7 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Foothills Hospital

    RECRUITING

    Calgary, Alberta, Canada

  • London Health Sciences Centre

    RECRUITING

    London, Ontario, Canada

  • Montreal Heart Institute

    RECRUITING

    Montreal, Quebec, Canada

  • QEIIHSC

    RECRUITING

    Halifax, Nova Scotia, B3H 3A7, Canada

  • Regina General Hospital

    RECRUITING

    Regina, Saskatchewan, Canada

  • Sunnybrook Hospital

    RECRUITING

    Toronto, Ontario, Canada

  • University of Ottawa Heart Institute

    RECRUITING

    Ottawa, Ontario, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.